HF
CERO

HRT Financial’s CERo Therapeutics CERO Stock Holding History

HRT Financial’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-40
Closed -$7K – 3385
2024
Q3 		$7K Buy
40
+34
+567% +$10.4K ﹤0.01% 2253
2024
Q2 		$3K Buy
+6
New +$13.9K ﹤0.01% 2070
2022
Q4 		– Sell
-7
Closed -$138K – 3282
2022
Q3 		$138K Hold
7
– – ﹤0.01% 2313
2022
Q2 		$135K Hold
7
– – ﹤0.01% 2362
2022
Q1 		$136K Hold
7
– – ﹤0.01% 2589
2021
Q4 		$137K Buy
+7
New +$139K ﹤0.01% 2676

Other funds holding CERO

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Selkirk Management Chatham, New Jersey $294M AUM 26.84% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HRT Financial's CERO Position: Q4 2024 in Review

HRT Financial sold out of CERo Therapeutics (CERO) in Q4 2024, closing a stake of 40 shares — an estimated $7K sold.

HRT Financial first reported a position in CERO in Q4 2021 and held it in 6 quarters. The position peaked at $138K in Q3 2022. 18 funds tracked by Wall St. Rank hold CERO as of Q4 2024.

  • HRT Financial reported no remaining CERo Therapeutics position as of Q4 2024 after selling out during the quarter.
  • HRT Financial sold 40 CERo Therapeutics shares in Q4 2024, an estimated $7K.
  • HRT Financial first reported a position in CERo Therapeutics in Q4 2021 and held it in 6 quarters.
  • HRT Financial's CERo Therapeutics position peaked at $138K in Q3 2022.
  • 18 funds tracked by Wall St. Rank held CERo Therapeutics as of Q4 2024.

Based on HRT Financial's 13F filing for Q4 2024, filed 14 Feb 2025.